Jones T. Nauseef

Also affiliated with Weill Cornell Medicine

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591”.

Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

Journal of Clinical Oncology(2023)10.1200/jco.23.00573

N/A

2.6DataRank · unranked

69 citations

Charlene Thomas, Oliver Sartor, Michael Sun, Judith Stangl‐Kremser, Mahelia Bissassar +10 more

Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going

Cancer Treatment Reviews(2024)10.1016/j.ctrv.2024.102748

N/A

0.891DataRank · unranked

28 citations

Charles L. Loprinzi, Jacob J. Orme, Regina M. Koch, Ahmed Mahmoud, Adam M. Kase +11 more

Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond

European Urology Focus(2021)10.1016/j.euf.2021.02.006

N/A

0.464DataRank · unranked

21 citations

Neil H. Bander, Scott T. Tagawa, Jones T. Nauseef

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer

JNCI Cancer Spectrum(2022)10.1093/jncics/pkac035

N/A

0.373DataRank · unranked

11 citations

Vaibhav G. Patel, Xiaobo Zhong, Luis A. Pina, Jessica E. Hawley, Emily Lin +17 more

Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5018

N/A

0.360DataRank · unranked

10 citations

Michael Philip Sun, Jones T. Nauseef, Charlene Thomas, Sandra Huicochea Castellanos, Joseph Earl Thomas +12 more

Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.5074

N/A

0.312DataRank · unranked

7 citations

Charlene Thomas, Jones T. Nauseef, Oliver Sartor, Michael Philip Sun, Sandra Huicochea Castellanos +14 more

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution

European Urology Oncology(2025)10.1016/j.euo.2025.05.014

N/A

0.269DataRank · unranked

5 citations

Marshall A. Diven, Brady Rippon, Christopher E. Barbieri, Jim C. Hu, Douglas S. Scherr +20 more

Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5100

N/A

0.269DataRank · unranked

5 citations

Joseph R. Osborne, Peter Gregos, Charlene Thomas, Mahelia Bissassar, Sharon Singh +14 more

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.158

N/A

0.176DataRank · unranked

1 citations

Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez +10 more

The Interplay between Mutagenesis and Extrachromosomal DNA Shapes Urothelial Cancer Evolution

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.05.07.538753

N/A

0.165DataRank · unranked

2 citations

William F. Hooper, Timothy R. Chu, Heather Geiger, Jennifer Shelton, Minita Shah +21 more

Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17007

N/A

0.104DataRank · unranked

1 citations

Juana Martinez Zuloaga, Kritika Subramanian, Peter Gregos, Mahelia Bissassar, Sharon Singh +13 more

Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort

PLoS Computational Biology(2024)10.1371/journal.pcbi.1011990

N/A

0.104DataRank · unranked

1 citations

Scott Kulm, Jones T. Nauseef, Zhengming Chen, Olivier Elemento, Kevin H. Kensler +2 more

Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.120

N/A

0.104DataRank · unranked

1 citations

Michael Sun, Jones T. Nauseef, Muhammad Junaid Niaz, Dunya Imad, Paul J. Christos +11 more

Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer

medRxiv(2025)10.1101/2025.07.01.25330467

N/A

0DataRank · unranked

0 citations

Alexander Martinez‐Fundichely, Sandra Cohen, Metin Balaban, Chen Khuan Wong, Weiling Li +26 more

Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps216

N/A

0DataRank · unranked

9 citations

Joseph R. Osborne, Matthew C. Dallos, Jones T. Nauseef, Cora N. Sternberg, Peter Gregos +11 more

Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.037

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Michael Sun, Oliver Sartor, Sharon Singh, Mahelia Bissassar +15 more

Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.077

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Benedict Ho, Juana Martinez Zuloaga, Brian D. Gonzalez, Michael Sun +15 more

Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men

Scientific Reports(2023)10.1038/s41598-023-35567-w

N/A

0DataRank · unranked

16 citations

J Gil Martínez, Sandra Huicochea Castellanos, Jana Ivanidze, Himanshu Nagar, Sean Nicholson +5 more